Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Barry Greenberg

Showing results (121-130 of 189) with videos related to

Pageof 19
Sort By:
Circulation|November 5, 2003
Myocardial contractile reserve by dobutamine stress echocardiography predicts improvement in ejection fraction with beta-blockade in patients with heart failure: the Beta-Blocker Evaluation of Survival Trial (BEST)Eric J Eichhorn, Paul A Grayburn, Susan A Mayer, et al.
European Journal of Heart Failure|November 14, 2019
Improving risk prediction in heart failure using machine learningEric D Adler, Adriaan A Voors, Liviu Klein, et al.
European Journal of Heart Failure|April 29, 2015
Rationale and design of a randomized, double-blind, event-driven, multicentre study comparing the efficacy and safety of oral rivaroxaban with placebo for reducing the risk of death, myocardial infarction or stroke in subjects with heart failure and significant coronary artery disease following an exacerbation of heart failure: the COMMANDER HF trialFaiez Zannad, Barry Greenberg, John G F Cleland, et al.
Circulation|June 20, 2007
Metoprolol reverses left ventricular remodeling in patients with asymptomatic systolic dysfunction: the REversal of VEntricular Remodeling with Toprol-XL (REVERT) trialWilson S Colucci, Theodore J Kolias, Kirkwood F Adams, et al.
ACS Pharmacology & Translational Science|October 18, 2024
Challenges and Opportunities for Consideration of Efavirenz Drug Repurposing for Alzheimer's Disease TherapeuticsBen Boyarko, Sonia Podvin, Barry Greenberg, et al.
Elife|January 19, 2023
Control of craniofacial development by the collagen receptor, discoidin domain receptor 2Fatma F Mohamed, Chunxi Ge, Shawn A Hallett, et al.
The New England Journal of Medicine|November 18, 2024
Phase 1 Study of AAV9.LAMP2B Gene Therapy in Danon DiseaseBarry Greenberg, Matthew Taylor, Eric Adler, et al.
Circulation|December 8, 2022
Complementary and Alternative Medicines in the Management of Heart Failure: A Scientific Statement From the American Heart AssociationSheryl L Chow, Biykem Bozkurt, William L Baker, et al.
Clinical Research in Cardiology : Official Journal of the German Cardiac Society|June 15, 2021
New-onset atrial fibrillation in patients with worsening heart failure and coronary artery disease: an analysis from the COMMANDER-HF trialJoão Pedro Ferreira, John G Cleland, Carolyn S P Lam, et al.
Scientific Reports|May 20, 2022
Inflammation and remodeling pathways and risk of cardiovascular events in patients with ischemic heart failure and reduced ejection fractionNicolas Girerd, John Cleland, Stefan D Anker, et al.
Pageof 19

Showing results (121-130 of 189) with videos related to

Sort By:
Pageof 19
Circulation|November 5, 2003
Myocardial contractile reserve by dobutamine stress echocardiography predicts improvement in ejection fraction with beta-blockade in patients with heart failure: the Beta-Blocker Evaluation of Survival Trial (BEST)Eric J Eichhorn, Paul A Grayburn, Susan A Mayer, et al.
European Journal of Heart Failure|November 14, 2019
Improving risk prediction in heart failure using machine learningEric D Adler, Adriaan A Voors, Liviu Klein, et al.
European Journal of Heart Failure|April 29, 2015
Rationale and design of a randomized, double-blind, event-driven, multicentre study comparing the efficacy and safety of oral rivaroxaban with placebo for reducing the risk of death, myocardial infarction or stroke in subjects with heart failure and significant coronary artery disease following an exacerbation of heart failure: the COMMANDER HF trialFaiez Zannad, Barry Greenberg, John G F Cleland, et al.
Circulation|June 20, 2007
Metoprolol reverses left ventricular remodeling in patients with asymptomatic systolic dysfunction: the REversal of VEntricular Remodeling with Toprol-XL (REVERT) trialWilson S Colucci, Theodore J Kolias, Kirkwood F Adams, et al.
ACS Pharmacology & Translational Science|October 18, 2024
Challenges and Opportunities for Consideration of Efavirenz Drug Repurposing for Alzheimer's Disease TherapeuticsBen Boyarko, Sonia Podvin, Barry Greenberg, et al.
Elife|January 19, 2023
Control of craniofacial development by the collagen receptor, discoidin domain receptor 2Fatma F Mohamed, Chunxi Ge, Shawn A Hallett, et al.
The New England Journal of Medicine|November 18, 2024
Phase 1 Study of AAV9.LAMP2B Gene Therapy in Danon DiseaseBarry Greenberg, Matthew Taylor, Eric Adler, et al.
Circulation|December 8, 2022
Complementary and Alternative Medicines in the Management of Heart Failure: A Scientific Statement From the American Heart AssociationSheryl L Chow, Biykem Bozkurt, William L Baker, et al.
Clinical Research in Cardiology : Official Journal of the German Cardiac Society|June 15, 2021
New-onset atrial fibrillation in patients with worsening heart failure and coronary artery disease: an analysis from the COMMANDER-HF trialJoão Pedro Ferreira, John G Cleland, Carolyn S P Lam, et al.
Scientific Reports|May 20, 2022
Inflammation and remodeling pathways and risk of cardiovascular events in patients with ischemic heart failure and reduced ejection fractionNicolas Girerd, John Cleland, Stefan D Anker, et al.
Pageof 19